Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Apollomics Starts China Trial of Immunotherapy for AML

publication date: Mar 4, 2021

Apollomics, a Bay Area-Hangzhou biopharma, started a China Phase I trial of uproleselan in patients with relapsed or refractory acute myeloid leukemia (AML). In 2020, Apollomics acquired China rights to uproleselan from GlycoMimetics in a two-drug, $189 million deal. Both drugs are novel E-selectin-based immunotherapies aimed at leukemia. Uproleselan is designed to block E-selectin from binding with blood cancer cells, which causes drug resistance. It will be administered along with chemotherapy. Apollomics was incubated by OrbiMed Asia to develop cancer immunotherapies. More details....

Stock Symbol: (NSDQ: GLYC)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.